CRISPR Therapeutics (NASDAQ: CRSP) has hired Tony Ho to serve as the company’s executive vice president and head of research and development. Switzerland-based CRISPR Therapeutics, which maintains its R&D operations in Cambridge, MA, is developing therapies based on the CRISPR gene-editing technology. Ho comes to the company from AstraZeneca (NYSE: AZN), where he was senior vice president and head of oncology integration and innovation.
From Our Partners · Special Report
Advice for funding and future transformational opportunities
Sponsored · Webinar
Phenotypic Screening & Profiling to Understand a Compound's Disease Impact
Eurofins Discovery
From Our Editors · Special Report
The AI, Big Data, and R&D Boom
